Clinical Evidence & Validation

Our validation program includes analytical and clinical studies aligned with CLIA Laboratory Developed Test (LDT) practices. As data lock occurs, we will publish sensitivity/specificity, PPV/NPV, calibration, and density‑stratified performance. LiquidMammo is not yet FDA‑cleared or FDA‑approved.

Why complementary screening is needed

The challenge in younger women

Mammography limitations are amplified in younger women due to higher breast density:

These statistics underscore why a complementary, non‑invasive, biology‑based signal may be especially valuable for younger, dense‑breasted populations.

References (public)